FDA Approves Combination of Nivolumab Plus Ipilimumab for mNSCLC

The FDA approved the combination of nivolumab plus ipilimumab as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1 ( ≥1%), as determined by an FDA-approved test.

Source: CancerNetwork - May 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news